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Parvovirus B19 viremia in children with systemic lupus erythematosus  
INTRODUCTION 
Human parvovirus B19 (PB19) is a single-stranded 
DNA virus that was first discovered in 1975 by 
Yvonne Cossart and her colleagues1. It has been 
associated with a variety of clinical manifestations, 
including rash, thrombocytopenia, leukopenia, fetal 
wastage, hypocomplementemia, autoimmune 
hemolytic anemia, arthritis and vasculitis2-6. It is the 
causative agent of erythema infectiosum (EI). In 
addition, B19 infection can be associated with 
elevated levels of antinuclear antibody, anti-double 
stranded DNA antibody, antineutrophil cytoplasmic 
antigens and anti-cardiolipin7. Also, 
antiphospholipid antibodies, when seen in acute 
parvovirus B19 infection, may have the same 
specificity and cofactor dependence as 
antiphospholipid antibodies associated with 
systemic lupus erythematosus8. 
B19 is a small, non-enveloped virus containing 
a single-stranded DNA of 5600 nucleotides and 
composed of two capsid proteins, VP1 (781 amino 
acids) and VP2 (554 amino acids), and a non-
structural protein, NS19,10. It targets early erythroid 
progenitor cells. It requires rapidly dividing cells in 
order to replicate. The cellular receptor is the P 
antigen (globoside, a glycosphingolipid), expressed 
in most individuals on mature erythrocytes and 
other cells11. B19 infection is found worldwide in 
persons of all ages. Most people become infected at 
some time during their life, up to 15% of 
individuals developing infection between 1 and 
5years of age, 15–60% between the ages of 5 and 
19yeas, and 30–60% in adulthood12.  
The detection of anti-VP1 and anti-VP2 
antibodies is the basis for the diagnosis of acute or 
past B19 virus infections. The dominant humoral 
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immune response is to VP2 during early 
convalescence and to VP1 during late 
convalescence. Anti-VP1 and anti-VP2 antibodies 
play a major role in limiting B19 infection in man13. 
Antibodies against NS1may have utility as an 
indicator of chronic or persistent forms of 
parvovirus B19 virus infection14.  
The association of B19 infection with 
autoimmune diseases, including systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), 
Sjögren's syndrome (SS), primary biliary cirrhosis 
(PBC) and polymyositis (PM), has been 
suggested5,6,15-18, although the exact relationship 
between the infection and these disorders is not 
understood. Recently, it has been suggested that 
B19 exacerbates or even induces SLE19,20. There are 
striking analogies between the clinical features and 
hematological findings of SLE and those of B19 
infection. 
This study was undertaken to investigate the 
seroprevalence of parvovirus B19 in SLE patients 
and to search for the different correlates of this 




This case-control study was conducted on 30 
children and adolescents fulfilling the American 
College of Rheumatology Classification Criteria for 
SLE younger than age of 16 years. They were 
13males and 17 females. Their ages ranged between 
9 and16 years with a mean age±SD: 12.7±1.8 years 
(median=13 years).They were recruited on one of 
their routine visits to the dermatology clinic, 
pediatric nephrology clinic, children’s Hospital, 
Zagazig University, Egypt. In addition, 20 age and 
sex matched healthy children were studied as 
controls. They were 14 males and 16 females. Their 
ages ranged between 11and 16 years with a mean 
age±SD: 13.3±1.2 years (median=13.7 years).They 
were recruited from the out patient clinic of the 
same hospital.  
All the children included in this study were 
subjected to detailed medical history with particular 
stress on age of the onset of SLE, the duration of 
the disease, any family history of autoimmune 
diseases and history of hospital admission. Cases 
and controls were asked about drugs which might 
affect anti-B19 antibodies level (e.g. steroids, 
cyclosporine, azathioprine and methotrexate) and 
had no associated illnesses (e.g. other 
inflammatory, immune infection or malignant 
diseases) which might affect B19 antibodies level 
before enrollment into the study. Also, antibodies 
against Epstein-Barr virus and cytomegalovirus 
were performed to be excluded from the study. 
Clinical examination was performed on patients 
and controls. For each patient, the clinical 
parameters of disease were also studied. These 
included the affection of various systems by the 
disease (skin, kidney, CNS, joints, serous 
membranes), and to exclude blood diseases and 
malignancies by chest, cardiac and abdominal 
examination, features of chronic anemia, 
hepatosplenomegaly. Assessment of growth by 
measuring weight and height and putting on their 
percentile was done.  
All individuals were subjected to the following 
investigations: 
a. Autoantibody profile (ANA and anti-dsDNA) by 
ELISA. 
b. complements(C 3, C4) levels by nephelometery.   
c. erythrocyte sedimentation rate (ESR) by 
Westergen method. 
d. anti-cardiolipin antibody (aCL) by ELISA. 
e. Detection of Parvovirus B19-DNA by nested 
PCR: 
Viral DNA was extracted using AxyPrep Body 
Fluid Viral DNA/RNA Miniprep Kit (Axygen; CA; 
USA) as directed by the manufacturer. Nested PCR 
was done according to Soliman et al.22.In the first 
round of amplification, 0.2µM of nucleotide 
primers corresponding to nucleotides 2381-
2400(B19S1) and 2781-2800 (B19AS1) (5' 
CCTTTTCTGTGCTAACCTGC-3' and 5'-
CCCAGGCTTGTGTAAGTC TT-3', respectively), 
were used. Two microlitres of each sample was 
used in a 50 µl reaction containing 5µl of 10x 
buffer (500mM Tris HCl,PH 8.7, 50 mM NH4Cl, 
20mM MgCl2, 400 mM KCl, 1% TritonX-100), 4µl 
of 25 mM dNTP, 1U of Tth  DNA polymerase and 
36 µl water. The reaction was overlaid with mineral 
oil. After an initial denaturation for 5 min at 94oC, 
38 cycles of denaturation (94oC for 45 sec), 
annealing (54oC for 45sec) and extension (72oC for 
1min). Two µl of the first PCR product was then 
added to the second round PCR mixture containing 
2µM of each oligonucleotide primers corresponding 
to nucleotides 2429-3448 (B19SII)  and 2730-2751 
(B19ASII) (5'-AAAGCTTTGTAGATTATGAG-3' 
and 5'-GGTTCTGCATGACTGCTATGG-3', 
respectively). Then 25 cycles of amplification were 
performed using the same parameters as the first 
round. Subsequently, the nested PCR products of 
size 322 base pairs (bp) were visualized by 
electrophoresis on 1% agarose gel together with a 
molecular weight marker. 
f. Quantitative measurement of Parvovirus B19 IgM 
and IgG antibodies by ELISA [RIDASCREEN 
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ParvovirusB19 IgM and IgG (r-biopharm, 
Darmstadt, Germany)] were used to determine the 
presence of specific IgM and IgG against 
parvovirus B19 VP1 and VP2. Levels>0.9 are 
considered positive.   
 
Statistical methods 
The data of the study was statistically analysed by 
SPSS (Statistical package for social sciences) 
version 15. Chi square test was used for comparison 
between studied groups. Spearman correlation 
coefficient rank test was used to rank different 






Table 1. Clinical manifestations of SLE patients 













Fever 4 (36.3)  5 (26.3)  >0.05
Rash 8 (72.7) 12 (63.1) >0.05
Arthritis 8 (72.7) 11 (57.8) >0.05
Serositis 3 (27.2)  5 (26.3)  >0.05
CNS 1 (9)  2 (10.5)  >0.05
RP 4 (36.3)  4 (21)  >0.05
High ESR 7 (63.3)  9 (47.3) >0.05
Cytopenia 6 (54.5)  10 (52.6) >0.05
ANA 7 (63.3)  10 (52.6) >0.05
Anti-dsDNA 4 (36.3)  7 (36.8) >0.05
Low C3/C4 8 (72.7) 5 (26.3)  <0.01
Proteinuria 4 (36.3)   8 (42.1) >0.05
aCL 1  (9)  3 (15.7)  >0.05
B19 IgM +ve 1(9)  9 (47.3) <0.05
B19 IgG +ve 2(18)  11(57.8) <0.05
*Numbers in parentheses are percentages. 
*CNS=central nervous system; ESR=erythrocyte sedimentation 
rate; ANA=antinuclear antibodies; anti-dsDNA=anti-double-






Table 2. Parvovirus B19 IgM and IgG antibodies 
levels in children with SLE. 
 
p 











0.01 1.3 (1.1) 0.45 (0.26) Mean (SD) 
 0.7 0.4 Median 
 0.1 0.2 Minimum 





0.03 4 (3.8) 0.65 (0.33) Mean (SD) 
 1.2 0.5 Median 
 0.45 0.3 Minimum 
 10 1.3 Maximum 
 
Table 2 shows that there is significant difference 
between IgG and IgM anti-B19 antibodies levels in 
SLE patients. 
 
Table 3. Correlation between anti-B19 
antibodies IgG and IgM levels in SLE patients. 
 
 B19 IgG (pg/dL) 
 r p 
B19 IgM (pg/dL) 0.942 <0.05      S 
 
Table 3 shows that there is positive correlation 
between the level of IgG and the level of IgM Ianti-




The relationship of parvovirus B19 infection with 
SLE is an issue of interest. There are striking 
similarities between B19 infection and SLE. It is 
difficult to differentiate B19 infection from SLE 
clinically6. Parvovirus B19 may be accompanied by 
a transient sub clinical state of autoimmunity21 and 
may mimic or exacerbate SLE6,20. It may be 
implicated in the development of SLE as well as 
other chronic arthropathies5,21.  
Kurtzman et al.23 demonstrated that the 
production of antibody to the B19 capsid protein 
plays a major role in limiting parvovirus infection 
in man. It has also been reported that, in the 
immunocompetent host, the production of B19 
specific antibodies results in clearance of the 
viremia within a few days, whereas in 
immunocompromised patients the virus persists14,24. 
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The appearance of B19 specific neutralizing 
antibodies might alter the course of viral infection. 
The persistence of infection with parvovirus B19 in 
our patients with SLE may have been due to lack of 
antibodies against parvovirus B19 because the host 
was immunocompromised or because of the use of 
immunosuppressive agents. However in El-Eishi et 
al.25 study, this is not feasible because both groups, 
the parvovirus positive and negative groups were on 
similar regimens of immunosuppression. 
Parvovirus B19 infection may have exacerbated 
the clinical course of SLE. However, there was no 
apparent association between the presence of B19 
DNA and other clinical manifestations, such as skin 
rash, arthritis and proteinuria, in patients with SLE. 
It seems that PB19 might induce either 
idiopathic SLE in a person who is genetically 
susceptible or it might induce a SLE-like picture26. 
In our study, Parvovirus B19 DNA was detected in 
11 of the 30 patients with SLE (33.3%) while it was 
not detected in any of our normal controls. Of the 
11 patients with B19 DNA, only two had IgG anti-
B19 antibody and one had IgM anti-B19 antibodies, 
whereas IgG and IgM anti-B19 antibodies were 
detected in 11 (57.8%) and 9 (47.3%) of 19 SLE 
patients without B19 DNA respectively. B19 DNA 
was found more commonly in sera from SLE 
patients without anti-B19 antibodies than in those 
with anti-B19 antibodies (p<0.05). In harmony with 
our results, El-Eishi et al.25 parvovirus could be 
detected in 30% of the SLE population studied and 
in none of the normal controls (p<0.05). Also,  Hsu 
et al.27 Parvovirus B19 DNA was detected in 17 of 
72 (24%) patients with SLE by PCR and was 
confirmed by Southern blotting and the prevalence 
of IgG and IgM anti-B19 antibodies in sera from 
SLE patients with B19 DNA was much lower than 
in patients without B19 DNA (p<0.05).  
In contrast to our study, El-Eishi et al.25 
studying the characteristics of the two groups of 
SLE patients, those with PCR positive and those 
with PCR negative test results, they could not detect 
any statistically significant differences between the 
two groups to help delineate a cause-effect 
relationship. Moreover, the two groups of patients 
were similarly immunosuppressed by steroids and 
cytotoxic agents in various combinations. 
The presence of B19 DNA in patients with SLE 
may not be causative. It may rather reflect a 
superimposed B19 infection in patients with SLE 
due to lack of antibodies against B19. 
As B19 DNA was detected only in patients with 
SLE, its clinical significance was studied further. 
Hypocomplementemia was significantly more 
common in patients with B19 viremia than in those 
without B19 DNA (p<0.05). Hsu et al.27 
demonstrated that hypocomplementemia and RP 
were significantly more common in patients with 
B19 viremia than in those without B19 DNA. We 
had questions that needed answers, firstly, if 
parvovirus B19 infection is a cause of SLE, 
secondly did it cause idiopathic SLE or it just 
induced a SLE-like picture that was not actually 
idiopathic SLE? Most of the case reports 
implicating parvovirus B19 as a cause of a lupus-
like illness described, in addition to the lupus-like 
clinical features, positive serological tests for SLE, 
including anti-Smith antibody and also the anti-
double stranded DNA which is considered by many 
investigators to be highly specific and committing 
for the diagnosis of idiopathic SLE. For this reason, 
we could not rely on any specific serological tests 
for differentiation between SLE and a parvovirus-
induced lupus-like syndrome; rather we relied on 
disease duration and the absence of renal affection. 
The disease duration of the self-limiting lupus-like 
disease induced by B19 infection tended to be two 
years or less in most of the reported cases. 
Concerning the absence of renal affection; El-Eishi 
et al.25 noted that the spectrum of clinical and 
serological features of such patients included 
common features and less common features. The 
common features included rash, fever, malaise, 
fatigue, arthritis, leucopenia, thrombocytopenia, 
and hypocomplementemia with a broad spectrum of 
autoantibodies. Less common ones were oral ulcers 
and Raynaud's phenomenon (a single report of 
each). As far as our knowledge, renal affection was 
never reported in the setting of the self-limiting 
lupus-like illness induced by parvovirus. 
Interestingly, this observation was never 
commented upon in the literature. However Hsu et 
al.27 noted that proteinuria was present in (35.3%) of 
SLE patients with B19 DNA and in (32.7%) of SLE 
patients without B19 DNA. 
The lupus illness is characterized by the 
classical features of SLE, which are the probability 
of renal disease and disease duration of not less 
than two years. On the other hand, the lupus-like 
disease does not have usually comprised renal 
affection and it runs a much more benign course 
than that of the idiopathic type.       
Nevertheless, in order to decide that disease 
duration less than two years duration and the 
absence of renal affection should suggest a 
parvovirus-induced lupus-like illness, further 
studies are needed. From this study, we suggested 
that B19 may exacerbate or even induces SLE by 
autoimmune mechanism (molecular mimicry), in 
favor to this theory, affinity purified anti-VP1 IgG 
Parvovirus B19 in children with SLE 
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from patient with skin rash and chronic B19 
arthritis has been found to cross react with human 
keratin, collagen type II, denatured DNA and 
cardiolipin28. 
Antibodies against Epstein-Barr virus and 
cytomegalovirus were performed to be excluded 
from the study as it was known that false positive 
ParvovirusB19 IgM and IgG results may be seen 
with other acute viral infection. Previous viral 
studies have shown antigenic relationship between 
peptides from the Epstein-Barr nuclear antigen and 
Sm, the latter associated mainly with SLE29.  
In conclusion parvovirus B19 might induce 
either idiopathic SLE in a person who is genetically 
susceptible or it might induce a SLE-like picture. 
B19 infection in patients with SLE may be due to 
lack of anti-B19 antibodies because of either the 
immunocompromised nature of the host or the use 
of immunosuppressive drugs. There was a higher 
prevalence of hypocomplementemia in patients 
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